01 — What PT-141 is
Bremelanotide, developed as PT-141, is a cyclic heptapeptide — seven amino acids in a closed ring — and a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH). It is a non-selective melanocortin receptor agonist, binding MC1R, MC3R, MC4R and MC5R. Its origins are in the melanocortin literature: the tanning peptide Melanotan II produced unexpected effects on sexual arousal in early work, and subsequent medicinal chemistry sought to separate that activity from pigmentation.
Unlike the PDE5 inhibitors — sildenafil, tadalafil and related compounds — which act peripherally on vascular smooth muscle, bremelanotide acts centrally. It activates melanocortin receptors in the hypothalamus that are implicated in the regulation of sexual desire, with MC4R in particular linked to sexual behaviour. That central mechanism is the basis of the claim that bremelanotide acts on desire rather than on the mechanics of erection, and it explains why its effects are described as not contingent on direct physical stimulation in the way a peripheral vasodilator's are.
This is a research context. PT-141 is not licensed for human use in the UK and is discussed here as a research compound only.
02 — The evidence: two pivotal RECONNECT trials
The licensed product rests on two identical Phase 3 trials, run as RECONNECT study 301 (NCT02333071) and study 302 (NCT02338960). Both were randomised, double-blind, placebo-controlled and multicentre, and both enrolled premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD). A combined 1,267 women were randomised; 1,247 and 1,202 respectively formed the safety and modified intention-to-treat populations.
Participants received a fixed subcutaneous dose on demand over 24 weeks, randomised 1:1 against placebo. The coprimary efficacy endpoints were the change from baseline to end of study in the Female Sexual Function Index desire domain (FSFI-D) and the distress item of the Female Sexual Distress Scale (FSDS-DAO item 13) — that is, one measure of desire and one measure of how much the low desire distressed the participant.
Both trials met both coprimary endpoints. Desire improved by 0.30 points in study 301 and 0.42 in study 302 (integrated 0.35), and distress fell by 0.37 and 0.29 points respectively (integrated 0.33), each statistically significant against placebo. The safety profile in the programme was dominated by tolerability effects rather than serious events, and most treatment-emergent adverse events were mild or moderate in intensity.
03 — Reading the effect sizes honestly
Peptide Data grades bremelanotide Moderate. The grade reflects two things held together: an adequately powered, replicated, statistically positive Phase 3 programme — which is more than most research peptides can claim — and absolute effect sizes that are small in the terms the scales use.
A change of roughly a third of a point on a desire domain is statistically reliable across 1,200-plus participants, but it is not large. Responder analyses identified a subset of participants who achieved more substantial gains, while others saw little; the trial authors and independent commentators have been explicit that the drug does not work for every woman and that the clinical meaningfulness of the average effect has been debated. Statistically robust and clinically modest are not in tension here — they are both true of the same dataset, and the honest reading keeps both in view.
The programme was also confined to a narrow, well-defined population: premenopausal women with acquired, generalised HSDD that is not attributable to another medical or psychiatric condition, relationship problems, or medication. That is a specific diagnosis, not "low libido" in general, and results in that population do not transfer to other groups.
04 — Safety: the label's two hard edges
The FDA prescribing information for the licensed product carries a contraindication in patients with uncontrolled hypertension or known cardiovascular disease, and states that the drug is not recommended for patients at high cardiovascular risk. The reason is haemodynamic: each dose produces a transient rise in blood pressure — maximum observed increases of about 6 mmHg systolic and 3 mmHg diastolic, peaking two to four hours after dosing — with a corresponding reduction in heart rate of up to 5 beats per minute. Blood pressure and heart rate usually return to baseline within about 12 hours, and no additive effect was seen with repeat dosing 24 hours apart.
The second edge is focal hyperpigmentation. It was reported by roughly 1% of patients who received up to eight doses per month, involving sites including the face, gums and breasts, with higher risk in people with darker skin and with more frequent dosing. Resolution was not confirmed in some patients, and the label advises considering discontinuation if it occurs.
Nausea is the most commonly reported treatment-emergent adverse event, seen in around 40% of participants in the programme, alongside flushing (around 20%) and injection-site reactions (around 12%). The pattern is consistent with the receptor pharmacology: melanocortin signalling also governs pigmentation, appetite and inflammation, so effects on those systems are expected rather than incidental.
05 — A programme that stopped short in men
Bremelanotide was also studied in men with erectile dysfunction, including men who had not responded to PDE5 inhibitors, and early intranasal work showed signals. Development for that indication was discontinued after elevations in blood pressure were observed with the intranasal formulation. The licensed product's label reflects this: it is indicated only for premenopausal women with acquired, generalised HSDD, and states explicitly that it is not indicated for postmenopausal women or men, nor to enhance sexual performance.
06 — Regulatory position: a US licence, no EU or UK authorisation
This is where jurisdictions diverge sharply, and it is the single most important fact for a UK reader. The FDA approved bremelanotide on 21 June 2019 under the brand name Vyleesi (developed by Palatin Technologies; the US licence held by AMAG Pharmaceuticals), for premenopausal women with acquired, generalised HSDD. It was the second drug approved for HSDD in that population, after flibanserin in 2015.
The European Medicines Agency has granted no marketing authorisation for bremelanotide, and no EU member state has authorised it; neither of the two US-approved HSDD drugs holds a centralised EU authorisation. The divergence reflects different evidentiary thresholds and risk–benefit calculations around cardiovascular signals and the subjective nature of sexual-desire endpoints, rather than a disagreement about the underlying data. There is likewise no UK marketing authorisation, so bremelanotide is not a licensed medicine in the UK and cannot be prescribed as one.
07 — What that means under UK law
Under the Human Medicines Regulations 2012, a substance requires a marketing authorisation from the MHRA before it may be sold or supplied for human therapeutic use, and making medicinal claims for an unlicensed product is a criminal offence. Because bremelanotide is a licensed prescription medicine in another jurisdiction, an imported product intended for human use would be treated as a prescription-only or unlicensed medicine in the UK, and supply outside the narrow exemption for the special clinical need of an individual patient is not permitted.
As a research peptide sold for laboratory use, PT-141 occupies a grey area: purchasable for legitimate research, but not for human consumption. The phrase "research use only" does not by itself confer legality. Where the surrounding presentation — packaging, website copy, or accompanying guidance — implies human use, the MHRA has treated that as unlicensed supply. The agency has a long enforcement record on melanocortin products marketed to people, dating back to its warnings on Melanotan, and in 2026 opened investigations into UK peptide clinics making medicinal claims. Readers should treat the labelling context, not the label text alone, as the operative legal test.
08 — Bottom line
Bremelanotide is a genuinely novel mechanism with a replicated Phase 3 programme behind it, and that is rare in this space. But its evidence sits at Moderate for defensible reasons: statistically positive results alongside modest absolute effect sizes in a narrowly defined population, a label constrained by a cardiovascular contraindication and a hyperpigmentation warning, a male-ED programme discontinued for blood-pressure reasons, and no UK licence.
For a UK reader the practical position is unambiguous: bremelanotide is a licensed medicine in the United States and an unlicensed research compound in the UK. It is not a UK-available treatment, and the research-use-only framing is the whole of its legal footing here.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.